Mucoadhesive Potential of Whey Protein Concentrate in Miconazole Mucoadhesive Prolong Release Tablets

Khairnar Akshay¹, Salunkhe Kishor², Chavan MJ¹, Chintamani Ravindra¹

¹Department of Pharmaceutics, Amrutvahini College of Pharmacy, Sangamner, Ahmednagar -422608, Maharashtra, India
²Sanjivani College of Pharmaceutical Education and Research, Sahajanaandnagar, Shinganapur, Kopargaon, Ahmednagar-423603, Maharashtra, India

ABSTRACT

Oral thrush (OPC) is one of the most frequent *Candida* infections of the oral cavity, this condition is common in patients with malnutrition, having chemotherapy, administrating immunosuppressive agents, or severe disease such as HIV. Prolong local administration of Miconazole is a must to treat OPC conditions in patients, which required the prolong mucoadhesion of the dosage form to provide local delivery of drugs for an extended time period with good mucoadhesion. Miconazole is a synthetic imidazole antifungal agent, various prescription and over the counter product available like Miconazole Gel, Topical cream, Immediate release Tablet available in the market but that lack in the prolonged period of action to the local mucosa. In the present study combination of Whey protein concentrate (WPC), Hydroxypropyl methylcellulose (HPMC) and Lactose were evaluated as a potential buccal adhesive tablet. The various combination of Whey protein concentrate with release controlling polymer was tested using a Miconazole as a potential antifungal agent. The mucoadhesive potential of WPC evaluated using Tensiometer by calculating the detachment force and drug release of Miconazole was performed to study the prolong release activity of Tablet. The optimized combination of WPC/HPMC/Lactose through a statistical study showed significant bioadhesion to the porcinemucosa and prolongdrug release for 10hrs.

INTRODUCTION

In recent years the effectiveness of formulation has been achieved through the controlled drug delivery platforms. Most of the work has been carried out in the area of bio adhesion, particularly the mucoadhesive drug delivery system, to improve the efficacy of drugs through oral, buccal, nasal route of administration (Patel et al., 2011). Common polymers that have been used as mucoadhesive drugs carrier are polyethylene oxide (Roy et al., 2009), Lecithin (Cook et al., 2017), Chitosan, Polymethyl acrylates, Carbopol, Poly-carbophil, Sodium CMC (Rao et al., 2013).

However, most of the polymers used in mucoadhesive drug delivery cause mucosal irritation limits its use in the therapeutic system (Ameye et al., 2005).

In the present study, an attempt has been made to evaluate the potential of Whey protein concentrate as a mucoadhesive agent in combination with Hydroxypropyl methylcellulose as release controlling agent (Biswas, 2016) for the Prolong delivery
of Miconazole is an antifungal agent (Sawyer et al., 1975).

Miconazole is a synthetic imidazole antifungal agent and most of the various prescription and over-the-counter products have been approved under various dosage forms like vaginal formulation (Kenechukwu et al., 2018), dermal formulations, oral, gel, topical formulations which can be administered orally, intravenously and intrathecally.

Miconazole also indicated for the treatment of Orophygial candidiasis (OPC) one of the most frequent Candida infections of the oral cavity. If it is left untreated, it may invade the esophagus or further progress to induce systemic complications. This condition is common in patients with malnutrition, having chemotherapy, administrating immunosuppressive agents, or severe diseases such as HIV (Hermant et al., 1997).

Prolong local administration of Miconazole is a must to treat OPC conditions in patients, which required the prolong mucoadhesion of the dosage form to provide local delivery of drugs for an extended time period with good mucoadhesion.

The Buccal administrations of drugs have gained interest as the oral cavity in disease conditions like OPC forms a convenient and easily accessible site for local and systemic delivery of the drug.

The present invention provides a carrier system with whey protein concentrate as a mucoadhesive agent to provide prolonged release bioadhesive therapeutic system that is essential for producing a long residence time in the locations of the infection in contrast to the usual local forms (mouthwashes, gel, pistils, lozenges) which have a transitional effect (L et al., 2019).

The Whey protein concentrate in combination with hydroxypropyl methylcellulose (HPMC) as a release controlling agent and Lactose monohydrate as a diluent come pore former have been evaluated in the present study as potential buccal bioadhesive tablets. The objective was to investigate the mucoadhesive potential of Whey protein concentrate in various combinations with release controlling polymer.

The bioadhesive strength of the WPC investigated and drug release characteristics evaluated with Miconazole as a potential antifungal drug.

The final combination of the polymer was optimized through the design of experiments using Mini Tab.

### MATERIALS AND METHODS

Miconazole API received from Gufic biosciences as a gift sample, Whey protein concentrate (WPC) purchased from NZMP, Hydroxypropyl methylcellulose (Methocel K15 LV) from Colorcon Ltd, Lactose monohydrate 450M from Armor Pharma, Microcrystalline cellulose (Avicel PH 102) from FMC, Colloidal silicon dioxide (Rochette ), Magnesium stearate (Merck), Talc (Merck)

#### Preparation of the Buccal Tablets

After some preliminary trials, the following excipients were finalize for the preparation of tablets, wherein Miconazole dose kept as 50mg and tablet weight finalized as 115mg. The list of ingredients listed in Table 1.

The various combination of WPC, HPMC and Lactose have been performed through the design of experiments (DOE) full factorial design.

The selection of design is based on the impacts of the factor for that full factorial design is chosen with three center points. Design details are as below mention Table 2 and the design of trials in Table 3.

![Figure 1: Half Normal Plot of detachment force](image1)

![Figure 2: Pareto Chart of Detachment Force](image2)
Table 1: List of ingredient

| S.No | Ingredient                                      | Functionality                        |
|------|------------------------------------------------|--------------------------------------|
| 1    | Miconazole                                     | Active Pharmaceutical ingredient     |
| 2    | Whey protein concentrate (WPC)                 | Mucoadhesive agent                   |
| 3    | Hydroxy propyl methyl cellulose (HPMC K15LV)   | Release controlling polymer          |
| 4    | Lactose Monohydrate (450M)                     | Diluent/Pore former                  |
| 5    | Microcrystalline cellulose (Avicel PH 102)     | Diluent                              |
| 6    | Talc                                           | Glidant                              |
| 7    | Magnesium stearate                             | Lubricant                            |

Table 2: Design details of factors

| Factors       | Base Design | Responses | Target          |
|---------------|-------------|-----------|-----------------|
| HPMC K 15     | 18          | 22        | Detachment Force| Maximum         |
| WPC           | 28          | 32        | Dissolution at 3 Hr. | 30 ± 10         |
| Lactose       | 6           | 10        | Dissolution at 6 Hr. | 65 ± 10         |
|               |             |           | Dissolution at 8 Hr. | At least 80 %   |

Table 3: Design of trials (run)

| Std Order | Run Order | HPMC K 15LV | Factors (mg/tablet) | Lactose |
|-----------|-----------|-------------|---------------------|--------|
| 1         | 1         | 18          | 28                  | 6      |
| 2         | 2         | 22          | 28                  | 6      |
| 3         | 3         | 18          | 32                  | 6      |
| 4         | 4         | 22          | 32                  | 6      |
| 5         | 5         | 18          | 28                  | 10     |
| 6         | 6         | 22          | 28                  | 10     |
| 7         | 7         | 18          | 32                  | 10     |
| 8         | 8         | 22          | 32                  | 10     |
| 9         | 9         | 20          | 30                  | 8      |
| 10        | 10        | 20          | 30                  | 8      |
| 11        | 11        | 20          | 30                  | 8      |

Manufacturing process

Miconazole, Whey protein concentrate (WPC), Hydroxypropyl methylcellulose (Hypermellose HPMC K15LV), Lactose Monohydrate (450M) mixed and granulated using purified water in High shear mixture granulator (HSMG) followed by drying. Milling and milled granules were lubricated with Microcrystalline cellulose (Avicel PH 102) 11mg/tablet or adjusted quantity, talc (1mg/tablet) and Magnesium stearate (1mg/tablet).

Tablet weight kept as 115mg and weight compensation done with Microcrystalline cellulose (Avicel PH102)

Compression of the tablets performed using Tablet compression machine (Cad Mach Single rotary 8 Station) with specially designed 8 mm tooling having concave at one side and flat at other.

The compression force was kept in the range of 6-8KP.

Evaluation/Characterization

Determination of physical parameters of tablets
Table 4: Bioadhesion and Drug release

| Std Order | Run Order | Factors | Detachment Force | Disso at 3 Hr | Disso at 6 Hr | Disso at 8 Hr |
|-----------|-----------|---------|------------------|--------------|--------------|--------------|
| 1         | 1         | 18 28 6 | 4.8              | 38           | 70           | 95           |
| 2         | 2         | 22 28 6 | 4.5              | 26           | 53           | 80           |
| 3         | 3         | 18 32 6 | 6.7              | 35           | 74           | 95           |
| 4         | 4         | 22 32 6 | 5.8              | 22           | 51           | 79           |
| 5         | 5         | 18 28 10| 5.3              | 32           | 71           | 90           |
| 6         | 6         | 22 28 10| 5.3              | 32           | 58           | 92           |
| 7         | 7         | 18 32 10| 6.2              | 35           | 74           | 93           |
| 8         | 8         | 22 32 10| 6.1              | 29           | 64           | 82           |
| 9         | 9         | 20 30 8 | 6.5              | 28           | 55           | 86           |
| 10        | 10        | 20 30 8 | 6.7              | 32           | 58           | 90           |
| 11        | 11        | 20 30 8 | 6.8              | 29           | 62           | 88           |

Table 5: Factorial Regression: Detachment Force versus HPMC K15, WPC, Lactose, Centre Pt

| S         | R-sq | R-sq(adj) | R-sq(pred) |
|-----------|------|-----------|------------|
| 0.152753  | 99.28% | 96.40% | *           |

Table 6: Analysis of Variance

| Source                | DF | Adj SS  | Adj MS  | F-Value | P-Value |
|-----------------------|----|---------|---------|---------|---------|
| Model                 | 8  | 6.42970 | 0.80371 | 34.44   | 0.029   |
| Linear                | 3  | 3.36375 | 1.12125 | 48.05   | 0.020   |
| HPMC K 15             | 1  | 0.21125 | 0.21125 | 9.05    | 0.095   |
| WPC                   | 1  | 3.00125 | 3.00125 | 128.62  | 0.008   |
| Lactose               | 1  | 0.15125 | 0.15125 | 6.48    | 0.126   |
| 2-Way Interactions    | 3  | 0.49375 | 0.16458 | 7.05    | 0.127   |
| HPMC K 15*WPC         | 1  | 0.06125 | 0.06125 | 2.63    | 0.247   |
| HPMC K 15*Lactose     | 1  | 0.15125 | 0.15125 | 6.48    | 0.126   |
| WPC*Lactose           | 1  | 0.28125 | 0.28125 | 12.05   | 0.074   |
| 3-Way Interactions    | 1  | 0.03125 | 0.03125 | 1.34    | 0.367   |
| HPMC K 15*WPC*Lactose | 1  | 0.03125 | 0.03125 | 1.34    | 0.367   |
| Curvature             | 1  | 2.54095 | 2.54095 | 108.90  | 0.009   |
| Error                 | 2  | 0.04667 | 0.02333 |         |         |
| Total                 | 10 | 6.47636 |         |         |         |

Table 7: Model Summary

| S         | R-sq | R-sq(adj) | R-sq(pred) |
|-----------|------|-----------|------------|
| 2.08167   | 95.80% | 78.98% | *          |
Table 8: Analysis of Variance

| Source                | DF | Adj SS    | Adj MS | F-Value | P-Value |
|-----------------------|----|-----------|--------|---------|---------|
| Model                 | 8  | 197.515   | 24.689 | 5.70    | 0.158   |
| Linear                | 3  | 132.375   | 44.125 | 10.18   | 0.091   |
| HPMC K 15             | 1  | 120.125   | 120.125| 27.72   | 0.034   |
| WPC                   | 1  | 6.125     | 6.125  | 1.41    | 0.357   |
| Lactose               | 1  | 6.125     | 6.125  | 1.41    | 0.357   |
| 2-Way Interactions    | 3  | 57.375    | 19.125 | 4.41    | 0.190   |
| HPMC K 15*WPC         | 1  | 6.125     | 6.125  | 1.41    | 0.357   |
| HPMC K 15*Lactose     | 1  | 45.125    | 45.125 | 10.41   | 0.084   |
| WPC*Lactose           | 1  | 3.125     | 3.125  | 0.72    | 0.485   |
| 3-Way Interactions    | 1  | 3.125     | 3.125  | 0.72    | 0.485   |
| HPMC K 15*WPC*Lactose | 1  | 3.125     | 3.125  | 0.72    | 0.485   |
| Curvature             | 1  | 4.640     | 4.640  | 1.07    | 0.409   |
| Error                 | 2  | 8.667     | 4.333  |         |         |
| Total                 | 10 | 206.182   |        |         |         |

Regression Equation in Uncoded Units

Disso at 3 Hr = 471 - 18.9 HPMC K 15 - 10.3 WPC - 64.9 Lactose + 0.406 HPMC K 15*WPC + 2.94 HPMC K 15*Lactose + 1.78 WPC*Lactose - 0.0781 HPMC K 15*WPC*Lactose - 1.46 Ct Pt

Table 9: Model Summary

| S         | R-sq | R-sq(adj) | R-sq(pred) |
|-----------|------|-----------|------------|
| 3.51188   | 96.55% | 82.73% | *          |

Table 10: Regression Equation in Uncoded Units

Disso at 6 Hr = -481 + 28.4 HPMC K 15 + 23.3 WPC + 68.4 Lactose - 1.22 HPMC K 15*WPC - 3.69 HPMC K 15*Lactose - 2.59 WPC*Lactose + 0.141 HPMC K 15*WPC*Lactose - 6.04 Ct Pt

Table 11: Model Summary

| S         | R-sq | R-sq(adj) | R-sq(pred) |
|-----------|------|-----------|------------|
| 2         | 97.59% | 87.94% | *          |

Figure 3: Half Normal plot

Figure 4: Pareto Chart
Table 12: Analysis of Variance

| Source                      | DF | Adj SS  | Adj MS  | F-Value | P-Value |
|-----------------------------|----|---------|---------|---------|---------|
| Model                       | 8  | 323.636 | 40.455  | 10.11   | 0.093   |
| Linear                      | 3  | 216.000 | 72.000  | 18.00   | 0.053   |
| HPMC K 15                   | 1  | 200.000 | 200.000 | 50.00   | 0.019   |
| WPC                         | 1  | 8.000   | 8.000   | 2.00    | 0.293   |
| Lactose                     | 1  | 8.000   | 8.000   | 2.00    | 0.293   |
| 2-Way Interactions          | 3  | 89.500  | 29.833  | 7.46    | 0.121   |
| HPMC K 15*WPC              | 1  | 24.500  | 24.500  | 6.12    | 0.132   |
| HPMC K 15*Lactose           | 1  | 60.500  | 60.500  | 15.13   | 0.060   |
| WPC*Lactose                 | 1  | 18.500  | 18.500  | 4.50    | 0.168   |
| 3-Way Interactions          | 1  | 18.000  | 18.000  | 4.50    | 0.168   |
| HPMC K 15*WPC*Lactose      | 1  | 18.000  | 18.000  | 4.50    | 0.168   |
| Curvature                   | 1  | 0.136   | 0.136   | 0.03    | 0.871   |
| Error                       | 2  | 8.000   | 4.000   |         |         |
| Total                       | 10 | 331.636 |         |         |         |

Regression Equation in Uncoded Units

\[
\text{Dissoat8Hr} = 852 - 39.9 \text{HPMC K 15} - 20.3 \text{WPC} - 120.1 \text{Lactose} + 1.063 \text{HPMC K 15*WPC} + 6.31 \text{HPMC K 15*Lactose} + 3.56 \text{WPC*Lactose} - 0.1875 \text{HPMC K 15*WPC*Lactose} - 0.25 \text{Ct Pt}
\]

Table 13: Parameters for Optimization

| Response   | Goal     | Lower | Target | Upper | Weight | Importance |
|------------|----------|-------|--------|-------|--------|------------|
| Disso at 8 Hr Target | 79.0     | 80.0  | 95     | 1     | 1      | 1          |
| Disso at 6 Hr Maximum    | 51.0     | 74.0  |       | 1     | 1      | 1          |
| Disso at 3 Hr Maximum    | 22.0     | 38.0  |       | 1     | 1      | 1          |
| Detachment Force Maximum | 4.5      | 6.8   |       | 1     | 1      | 1          |

Table 14: Solution for optimization

| Solution | HPMC K 15 | WPC | Lactose | Disso at 8 Hr Fit | Disso at 6 Hr Fit | Disso at 3 Hr Fit | Detachment Force Fit |
|----------|-----------|-----|---------|------------------|------------------|------------------|----------------------|
| 1        | 22        | 32  | 10      | 82               | 64               | 29               | 6.1                  |

Table 15: Multiple Response Prediction

| Variable | Setting |
|----------|---------|
| HPMC K 15 | 22      |
| WPC      | 32      |
| Lactose  | 10      |

| Disso at 8 Hr | Fit | SE Fit | 95% CI         | 95% PI          |
|---------------|-----|--------|----------------|-----------------|
| 82.00         | 2.00|        | (73.39, 90.61) | (69.83, 94.17)  |
| Disso at 6 Hr | 64.00| 3.51 | (48.89, 79.11) | (42.63, 85.37)  |
| Disso at 3 Hr | 29.00| 2.08 | (20.04, 37.96) | (16.33, 41.67)  |
| Detachment Force | 6.100| 0.153| (5.443, 6.757) | (5.171, 7.029)  |
Table 16: Actual Trial Results

| Solution | HPMC 15 | K | WPC   | Lactose | Disso at 8 Hr Fit | Disso at 6 Hr Fit | Disso at 3 Hr Fit | Detachment Force Fit |
|----------|---------|---|-------|---------|------------------|------------------|------------------|---------------------|
| 1        | 22      | 32| 10    | 80      | 65               | 39               | 6                |

Drug Release studies

Dissolution of all tablets was performed at the following condition (www.accessdata.fda.gov)

Apparatus USP I Basket, RPM 50, Medium pH 6.5 phosphate buffer with 0.5 % Sodium Lauryl Sulphate, Volume 1000mL, Timepoints 1Hrs, 3Hrs, 4Hrs, 6Hrs, 8Hrs and 10hrs. Results of the same shown in Table 4.

RESULTS AND DISCUSSION

Physical parameters of Tablets

Thickness: Avg : 2.2mm (n:12), Hardness : 3.1kp (n:12), Weight: 115.3 (n:12), Friability 0.06 %

Interpretation

From the above plots half-normal plot, Pareto chart and Interaction plot, it can be depicting that WPC is the most impacting factor on Dissolution at 3 Hr. As the concentration of the WPC increase, then Dissolution is also increasing. Tables 5 and 6, Figure 1 and Figure 2.

Dissolution at 3hrs

Impact of dissolution at 3hrs shown in Tables 7 and 8, Figure 3 and Figure 4.

Interpretation

From the above plots half-normal plot, Pareto chart and Interaction plot, it can be depicting that HPMC K 15 is the most impacting factor on Dissolution at 3 Hr. As the concentration of the HPMC increase, then Dissolution is also increasing.

Dissolution at 6 Hr

Tablet thickness, Hardness, weight variation, friability test (www.usp.org›document›gen-chapter) performed as per USP and recorded.

Ex-vivo determination of bio adhesion In Vitro comparative bio adhesion study (peak detachment force) through Tensiometer (Jackson, 2001).

Porcine gingiva was obtained from slaughterhouse the mucosPO4,8.0g NaCl a were stored at −20 °C in isotonic buffered saline pH 7.4 (2.38 g Na2HP04-H20, 0.19 g KH2P04,8.0g) NaCl made up to 1000 ml with demineralized water. The porcine gingival tissue was attached with glue to the plate of the tensiometer. After hydrating the mucosa with 15_1 of the isotonic phosphate-buffered saline, the tablet was fixed on the mucosa applying a force of 0.5N for 5 min. After the initial contact, the thermostatic beaker (37 °C) was filled with 125 ml isotonic buffered saline pH 7.4 at 37 °C. Next, the tablet and mucosa were pulled apart at a speed of 5mmmin−1 until a complete ru and detachment force was recorded listed in Table 4.
Impact of dissolution at 6hrs shown in Tables 9 and 10, Figure 5 and Figure 6.

**Interpretation**

From the above plots half-normal plot, Pareto chart and Interaction plot, it can be depicting that HPMC K 15 is the most impacting factor on Dissolution at 6 Hr. As the concentration of the HPMC increase, then Dissolution is also increasing.

**Response**

**Dissolution at 8 Hr**

Impact of dissolution at 6hrs shown in Tables 11 and 12, Figure 7.

**Interpretation**

From the above plots half-normal plot, Pareto chart and Interaction plot, it can be depicting that HPMC K 15 is the most impacting factor on Dissolution at 8 Hr. As the concentration of the HPMC increase then Dissolution is also increasing.

**Optimization**

Optimized parameters were shown in Tables 13, 14, 15 and 16.

**Inference**

Above mention Trail was conducted for optimization predicted results and actual results are well within the limit. Hence it can be said that the product is optimized from above setting parameters with 95% CI.

**CONCLUSIONS**

The mucoadhesive potential of Whey protein concentrate has been investigated using Miconazole as a Model antifungal drug through the various combination with HPMC K15LV as a release controlling polymer. The optimized quantity of Whey protein (32mg/tablet) found to be providing good bioadhesive/mucoadhesive strength calculated using a tensiometer. The prolonged-release of Miconazole was obtained and an optimized combination of Whey protein, HPMC and Lactose have been established, which can be used as a platform technology for mucoadhesive drug delivery.

**ACKNOWLEDGEMENT**

Mr. Mandar Kor for supporting in statistical evaluation of data.

**REFERENCES**

Ameye, D., Mus, D., Foreman, P., Remon, J. P. 2005. Spray-dried Amioca starch/Carbopol 974P mix-

ures as buccal bioadhesive carriers. *International Journal of Pharmaceutics*, 301(1-2):170–180.

Biswas, R. 2016. Hydroxy Propyl Methyl Cellulose: Different Aspects of Drug Delivery. *Journal of Pharmacy and Pharmacology*, 4:381–385.

Cook, S. L., Bull, S. P., Methven, L., Parker, J. K., Khutoryanskiy, V. V. 2017. Mucoadhesion: A food perspective. *Food Hydrocolloids*, 72:281–296.

Hermant, C., Luc, J., Roques, C., Petureau, F., Escamilla, R., Federlin-Ducani, M. 1997. Activité fongicide in vitro de différents bains de bouche sur la flore fongique gingivale de patients infectés par le VIH. *Médecine et Maladies Infectieuses*, 27:80181–80184.

Jackson, S. 2001. In vitro assessment of the mucoadhesion of cholestyramine to the porcine and human gastric mucosa. *European Journal of Pharmaceutics and Biopharmaceutics*, 52(2):121–127.

Kenechukwu, F. C., Attama, A. A., Ibezim, E. C., Nnamani, P. O., Umeyor, C. E., Uronnachi, E. M., Ozioko, A. C. 2018. Novel Intravaginal Drug Delivery System Based on Molecularly PEGylated Lipid Matrices for Improved Antifungal Activity of Miconazole Nitrate. *BioMed Research International*, pages 1–18.

L, S., et al. 2019. U.S Food and Drug Administration. Dissolution Methods. U.S Department of Health and Hygenic.

Patel, K. V., Dodiya, P. N. D., .., H. D., .., S. P. K. 2011. Buccal Bioadhesive Drug Delivery System: An Overview. *International Journal of Pharmaceutical & Biological Archives*, 2(2):600–609.

Rao, R., Shravan, N. G., Mettu, B., .., R. 2013. Overview of Buccal Drug Delivery Systems. 5:80–88.

Roy, S., Pal, K., Anis, A., Pramanik, K., Prabhakar, B. 2009. Polymers in Mucoadhesive Drug-Delivery Systems: A Brief Note. *Designed Monomers and Polymers*, 12(6):483–495.

Sawyer, P. R., Brogden, R. N., Pinder, R. M., Speight, T. M., .., A. G. 1975. Miconazole: a review of its antifungal activity and therapeutic efficacy. *Drugs*, 9(6):406–423.